Rubenstein M - Search Results

1

Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.

Lievano G, Di Domenico D, Brown J, Bridges P, Rubenstein M, Shaw M, Guinan P. Lievano G, et al. Among authors: rubenstein m. Methods Find Exp Clin Pharmacol. 1997 May;19(4):261-7. Methods Find Exp Clin Pharmacol. 1997. PMID: 9228652

2

Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.

Rubenstein M, Tsui P, Guinan P. Rubenstein M, et al. Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):515-8. doi: 10.1358/mf.2006.28.8.1003571. Methods Find Exp Clin Pharmacol. 2006. PMID: 17136230 Free article.

3

Orthotopic placement of the Dunning R3327 AT-3 prostate tumor in the Copenhagen X Fischer rat.

Rubenstein M, Saffrin R, Shaw M, Muchnik S, Guinan P. Rubenstein M, et al. Prostate. 1995 Sep;27(3):148-53. doi: 10.1002/pros.2990270305. Prostate. 1995. PMID: 7567693

4

Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo.

Lievano G, Mirochnik Y, Rubenstein M, Shaw M, Guinan P. Lievano G, et al. Among authors: rubenstein m. Methods Find Exp Clin Pharmacol. 1996 Dec;18(10):659-62. Methods Find Exp Clin Pharmacol. 1996. PMID: 9121221

5

Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.

Shaw M, Ratanawong S, Chou P, Ray V, Mirochnik Y, Slobodskoy L, Rubenstein M, Guinan P. Shaw M, et al. Among authors: rubenstein m. Methods Find Exp Clin Pharmacol. 1998 Mar;20(2):111-4. doi: 10.1358/mf.1998.20.2.481838. Methods Find Exp Clin Pharmacol. 1998. PMID: 9604852 Free article.

6

Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.

Guinan P, Shaw M, Mirochnik Y, Slobodskoy L, Ray V, Rubenstein M. Guinan P, et al. Among authors: rubenstein m. Methods Find Exp Clin Pharmacol. 1998 Nov;20(9):739-42. Methods Find Exp Clin Pharmacol. 1998. PMID: 10022026

7

Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides.

Rubenstein M, Mirochnik Y, Chou P, Guinan P. Rubenstein M, et al. Methods Find Exp Clin Pharmacol. 1998 Dec;20(10):825-31. doi: 10.1358/mf.1998.20.10.487534. Methods Find Exp Clin Pharmacol. 1998. PMID: 10091218 Free article.

8

In vivo establishment of T98G human glioblastoma.

Rubenstein M, Shaw M, Mirochnik Y, Slobodskoy L, Glick R, Lichtor T, Chou P, Guinan P. Rubenstein M, et al. Methods Find Exp Clin Pharmacol. 1999 Jul-Aug;21(6):391-3. doi: 10.1358/mf.1999.21.6.541918. Methods Find Exp Clin Pharmacol. 1999. PMID: 10445230 Free article.

9

Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines.

Rubenstein M, Mirochnik Y, Slobodskoy L, Guinan P. Rubenstein M, et al. Methods Find Exp Clin Pharmacol. 2001 Nov;23(9):487-90. doi: 10.1358/mf.2001.23.9.662136. Methods Find Exp Clin Pharmacol. 2001. PMID: 11876021 Free article.

10

Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.

Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Rubenstein M, et al. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):649-52. doi: 10.1358/mf.2002.24.10.802313. Methods Find Exp Clin Pharmacol. 2002. PMID: 12616956 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters